AtriCure/$ATRC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AtriCure
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Ticker
$ATRC
Sector
Primary listing
Industry
Health Care Equipment and Supplies
Headquarters
Employees
1,300
Website
AtriCure Metrics
BasicAdvanced
$1.7B
-
-$0.77
1.56
-
Price and volume
Market cap
$1.7B
Beta
1.56
52-week high
$43.11
52-week low
$20.20
Average daily volume
550K
Financial strength
Current ratio
3.94
Quick ratio
2.67
Long term debt to equity
16.005
Total debt to equity
16.631
Interest coverage (TTM)
-5.66%
Profitability
EBITDA (TTM)
-14.152
Gross margin (TTM)
74.71%
Net profit margin (TTM)
-7.27%
Operating margin (TTM)
-6.82%
Effective tax rate (TTM)
-3.08%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-3.53%
Return on equity (TTM)
-7.85%
Valuation
Price to revenue (TTM)
3.323
Price to book
3.75
Price to tangible book (TTM)
9.83
Price to free cash flow (TTM)
200.497
Free cash flow yield (TTM)
0.50%
Free cash flow per share (TTM)
0.175
Growth
Revenue change (TTM)
16.28%
Earnings per share change (TTM)
-11.03%
3-year revenue growth (CAGR)
18.19%
10-year revenue growth (CAGR)
15.54%
3-year earnings per share growth (CAGR)
-12.55%
10-year earnings per share growth (CAGR)
2.67%
What the Analysts think about AtriCure
Analyst ratings (Buy, Hold, Sell) for AtriCure stock.
Bulls say / Bears say
AtriCure reported a 13.6% year-over-year increase in worldwide revenue for Q1 2025, reaching $123.6 million, indicating strong financial performance. (AtriCure Q1 2025 Financial Results)
The company launched the AtriClip PRO-Mini® device in April 2025, expanding its product portfolio and potentially increasing market share. (AtriCure Announces First Use of the AtriClip PRO-Mini® Device)
Analysts from Piper Sandler raised their price target for AtriCure from $40.00 to $50.00 in February 2025, reflecting confidence in the company's growth prospects. (AtriCure Stock Price Expected to Rise, Piper Sandler Analyst Says)
In March 2025, AtriCure's stock price declined by 6% following insider selling by Director Karen Prange, which may signal concerns about the company's valuation. (AtriCure Stock Price Down 6% Following Insider Selling)
The stock experienced a 6.8% drop in March 2025 after an analyst downgrade, potentially indicating reduced confidence in future performance. (AtriCure Stock Price Down 6.8% on Analyst Downgrade)
AllianceBernstein L.P. reduced its holdings in AtriCure by 3.4% in Q4 2024, suggesting some institutional investors may be reevaluating their positions. (AllianceBernstein L.P. Has $117.21 Million Stock Holdings in AtriCure)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AtriCure Financial Performance
Revenues and expenses
AtriCure Earnings Performance
Company profitability
AtriCure News
AllArticlesVideos
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
Business Wire·3 days ago
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
Business Wire·4 days ago
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AtriCure stock?
AtriCure (ATRC) has a market cap of $1.7B as of August 01, 2025.
What is the P/E ratio for AtriCure stock?
The price to earnings (P/E) ratio for AtriCure (ATRC) stock is 0 as of August 01, 2025.
Does AtriCure stock pay dividends?
No, AtriCure (ATRC) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next AtriCure dividend payment date?
AtriCure (ATRC) stock does not pay dividends to its shareholders.
What is the beta indicator for AtriCure?
AtriCure (ATRC) has a beta rating of 1.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.